Prescription medicine
Gabapentin Brand names: Neurontin, Gralise, Relgaabi, Gabarone
Gabapentin (Neurontin) is a prescription medicine with an FDA approval on record since 1993. FDA's NDC Directory lists it from 85 generic labelers, and pharmacies paid $0.0218 per gabapentin 100 mg capsule in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the gabapentin FDA label on DailyMed (effective May 12, 2026, Viatris Specialty LLC); the NDA 20235 record on Drugs@FDA; every gabapentin label on DailyMed.
Highlights of the record
FDA label of May 12, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageNEURONTIN ® is indicated for:
Management of postherpetic neuralgia in adults
Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy NEURONTIN is indicated for:
Postherpetic neuralgia in adults ( 1 )
Adjunctive therapy in the treatment of partial onset seizures, with and without secondary general
Forms and strengths
- 100 mg
- 200 mg
- 300 mg
- 400 mg
- 450 mg
- 600 mg
- 750 mg
- 800 mg
- 900 mg
- 50 mg/ml
- 250 mg/5ml
Capsule; tablet; film-coated tablet; coated tablet; solution.
On the market
- Earliest approval on file
- December 30, 1993 Neurontin, Viatris; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 70 first September 12, 2003; 44 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 89 of which 85 under generic applications, 3 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.0218 per capsule Gabapentin 100 mg capsule
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 22 since 2013 0 Class I among all firms' recalls; latest October 10, 2025
- FAERS reports
- 362,654 through July 30, 2026
What is gabapentin used for?
From the label: indications and usageNEURONTIN ® is indicated for:
Management of postherpetic neuralgia in adults
Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy NEURONTIN is indicated for:
Postherpetic neuralgia in adults ( 1 )
Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy
Conditions named in the indications of gabapentin's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Anti-epileptic Agent.
Source: FDA drug label (Neurontin), Viatris Specialty LLC, effective May 12, 2026 (SPL set 97935fd9-1d4a-43b6-a5d9-de994591187b), via openFDA; the full label on DailyMed
What does the patient leaflet for gabapentin say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about NEURONTIN?Do not stop taking NEURONTIN without first talking to your healthcare provider. Stopping NEURONTIN suddenly can cause serious problems. NEURONTIN can cause serious side effects including: 1. Suicidal Thoughts. Like other antiepileptic drugs, NEURONTIN may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. This can happen while you take NEURONTIN as well as after stopping NEURONTIN. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: 2. thoughts about suicide or dying 3. attempts to commit suicide 4. new or worse depression 5. new or worse anxiety 6. feeling agitated or restless 7. panic attacks 8. trouble sleeping (insomnia) 9. new or worse irritability 10. acting aggressive, being angry, or violent 11. acting on dangerous impulses 12. an extreme increase in activity and talking (mania) 13. other unusual changes in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions? 14. Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. 15. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. Do not stop taking NEURONTIN without first talking to a healthcare provider. 16. Stopping NEURONTIN suddenly can cause serious problems. Stopping a seizure medicine suddenly in a person who has epilepsy can cause seizures that will not stop (status epilepticus). 17. Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. 18. Changes in behavior and thinking. […]
From the patient leaflet: What should I avoid while taking NEURONTIN?Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking NEURONTIN without first talking with your healthcare provider. Taking NEURONTIN with alcohol or drugs that cause sleepiness or dizziness may make your sleepiness or dizziness worse. • Do not drive, operate heavy machinery, or do other dangerous activities until you know how NEURONTIN affects you. NEURONTIN can slow your thinking and motor skills.
From the patient leaflet: How should I store NEURONTIN?Store NEURONTIN capsules and tablets at room temperature between 68°F to 77°F (20°C to 25°C). • Store NEURONTIN oral solution in the refrigerator between 36°F to 46°F (2°C to 8°C). Keep NEURONTIN and all medicines out of the reach of children.
Source: FDA drug label (Neurontin), Viatris Specialty LLC, effective May 12, 2026 (SPL set 97935fd9-1d4a-43b6-a5d9-de994591187b), via openFDA; the full label on DailyMed
Is there a generic for gabapentin (Neurontin)?
The FDA approved the first generic gabapentin on September 12, 2003. 70 generic applications are approved; 44 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists gabapentin from 85 labelers under a generic (ANDA) application and from 3 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1993 earliest approval on file
- 2003 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for gabapentin (Neurontin)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.0218 per Gabapentin 100 mg capsule, about the same as a year earlier. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Gabapentin 100 mg capsule (generic)
- Neurontin 300 mg capsule (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Gabapentin 100 mg capsule | Generic | $0.0218 per capsule | $0.655 | +0.9% |
| Gabapentin 250 mg/5 mL solution | Generic | $0.0876 per mL | n/a | -2% |
| Gabapentin 300 mg capsule | Generic | $0.0314 per capsule | $0.943 | -10% |
| Gabapentin 400 mg capsule | Generic | $0.0422 per capsule | $1.27 | -3% |
| Gabapentin 600 mg tablet | Generic | $0.064 per tablet | $1.92 | -13% |
| Gabapentin 800 mg tablet | Generic | $0.0883 per tablet | $2.65 | -13% |
| Gabapentin ER 300 mg tablet | Generic | $0.638 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $19.15 | -66% |
| Gabapentin ER 600 mg tablet | Generic | $1.02 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $30.75 | -46% |
| Relgaabi 300 mg capsule | Generic | $0.0314 per capsule | $0.943 | n/a |
| Relgaabi 400 mg capsule | Generic | $0.0422 per capsule | $1.27 | n/a |
| Gabarone 100 mg tablet | Brand | $8.79 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $263.67 | n/a |
| Gabarone 400 mg tablet | Brand | $8.57 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $257.13 | n/a |
| Gralise ER 300 mg tablet | Brand | $10.19 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $305.55 | -0.4% |
| Gralise ER 450 mg tablet | Brand | $10.14 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $304.28 | -0.2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has gabapentin been recalled?
The FDA's Enforcement Report lists 22 recalls naming gabapentin since 2013: 0 Class I (the most serious), 15 Class II, 7 Class III; 7 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| October 10, 2025 | Class II | The Harvard Drug Group LLC | Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity . |
| June 19, 2025 | Class II | The Harvard Drug Group LLC | Defective container; blister packaging inadequately sealed. |
| March 13, 2025 | Class II | Glenmark Pharmaceuticals Inc., USA | CGMP Deviations |
| March 4, 2025 | Class III | SUN PHARMACEUTICAL INDUSTRIES INC | Cross Contamination |
| July 31, 2024 | Class II | Granules Pharmaceuticals Inc. | Presence of Foreign Tablets; 3 fused tablets of Metformin ER 500 mg were found in bottle of Gabapentin Tablets |
| April 24, 2023 | Class III | The Harvard Drug Group | Product mixup: one foreign tablet found in product. |
| February 17, 2023 | Class III | Sciegen Pharmaceuticals Inc | Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles. |
| March 8, 2021 | Class II | Akorn, Inc. | Failed Impurities/Degradation Specifications; out of specification for unknown impurity observed during 6 month stability testing |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the gabapentin label say about other medicines?
The gabapentin label names 15 other medicines in its interaction, contraindication or warning sections. The labels of 24 other medicines name gabapentin. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Buprenorphine | drug interactions | Respiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e.g., morphine, hydrocodone, oxycodone, buprenorphine) [see Warnings and Precautions (5.8) ]. |
| Carbamazepine | drug interactions | Carbamazepine Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg three times a day; |
| Cimetidine | drug interactions | This decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance. |
| Divalproex | drug interactions | Valproic Acid The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg three times a day; |
| Gabapentin enacarbil | warnings and precautions | Driving performance studies conducted with a prodrug of gabapentin (gabapentin enacarbil tablet, extended-release) indicate that gabapentin may cause significant driving impairment. |
| Hydrocodone | drug interactions | Hydrocodone Coadministration of NEURONTIN with hydrocodone decreases hydrocodone exposure [see Clinical Pharmacology (12.3) ]. |
| Magnesium hydroxide | drug interactions | Maalox ® (aluminum hydroxide, magnesium hydroxide) The mean bioavailability of gabapentin was reduced by about 20% with concomitant use of an antacid (Maalox ® ) containing magnesium and aluminum hydroxides. |
| Morphine | drug interactions | DRUG INTERACTIONS Concentrations increased by morphine; may need dose adjustment |
| Naproxen | drug interactions | Naproxen Coadministration (N=18) of naproxen sodium capsules (250 mg) with NEURONTIN (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%. |
| Norethindrone | drug interactions | Oral Contraceptive Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg three times a … |
| Oxycodone | drug interactions | Respiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e.g., morphine, hydrocodone, oxycodone, buprenorphine) [see Warnings and Precautions (5.8) ]. |
| Phenobarbital | drug interactions | Phenobarbital Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg three times a day; |
| Phenytoin | drug interactions | Phenytoin In a single (400 mg) and multiple dose (400 mg three times a day) study of NEURONTIN in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin … |
| Probenecid | drug interactions | Probenecid Probenecid is a blocker of renal tubular secretion. Gabapentin pharmacokinetic parameters without and with probenecid were comparable. |
Every other medicine the gabapentin label names
| Medicine named | Section | What the label says |
|---|---|---|
| Valproic acid | drug interactions | Valproic Acid The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg three times a day; |
Other labels that name gabapentin
Source: FDA drug label (Neurontin), Viatris Specialty LLC, effective May 12, 2026 (SPL set 97935fd9-1d4a-43b6-a5d9-de994591187b), via openFDA; the full label on DailyMed
What do FAERS reports show for gabapentin?
The FDA Adverse Event Reporting System holds 362,654 reports that list gabapentin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 34,219 are coded as a death and 106,727 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as gabapentin?
14 other medicines are given the same way (oral) and in the same FDA class as gabapentin or labeled mainly for the same use (nerve pain and fibromyalgia), the same class first. Nerve pain and fibromyalgia lists all 6 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Lamotrigine | Seizures and epilepsy | 50 labelers | $0.0268 per tablet 25 mg tablet | A presentation being discontinued |
| Divalproex | Seizures and epilepsy | 44 labelers | $0.194 per tablet 500 mg tablet | No current entry |
| Oxcarbazepine | Seizures and epilepsy | 43 labelers | $0.167 per tablet 300 mg tablet | No current entry |
| Zonisamide | Seizures and epilepsy | 20 labelers | $0.106 per capsule 100 mg capsule | No current entry |
| Valproic acid | Seizures and epilepsy | 19 labelers | $0.243 per capsule 250 mg capsule | Listed; available |
| Phenytoin | Seizures and epilepsy | 23 labelers | $0.145 per capsule 100 mg capsule | No current entry |
| Primidone | Seizures and epilepsy | 21 labelers | $0.0914 per tablet 50 mg tablet | No current entry |
| Felbamate | Seizures and epilepsy | 9 labelers | $1.00 per tablet 600 mg tablet | No current entry |
Every medicine labeled for the same conditions as gabapentin
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does gabapentin compare with medicines for the same use?
15 side-by-side pages set gabapentin beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to gabapentin
- 14 medicines for the same use
- Other anti-seizure medicines
- the pharmacologic class, with prices and generics
- Gabapentin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other